Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) | Zendy

Anna M.M. van Deursen | Zendy; Marlies A. van Houten | Zendy; Chris Webber | Zendy; Michael A. Patton | Zendy; Daniel A. Scott | Zendy; Scott D. Patterson | Zendy; Mohinder Sidhu | Zendy; Wayne Drews | Zendy; William C. Gruber | Zendy; Emilio A. Emini | Zendy; Diederick E. Grobbee | Zendy; Marc J. M. Bonten | Zendy; Elisabeth A. M. Sanders | Zendy

Open Access

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Author(s) -

Anna M.M. van Deursen,

Marlies A. van Houten,

Chris Webber,

Michael A. Patton,

Daniel A. Scott,

Scott D. Patterson,

Mohinder Sidhu,

Wayne Drews,

William C. Gruber,

Emilio A. Emini,

Diederick E. Grobbee,

Marc J. M. Bonten,

Elisabeth A. M. Sanders

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix419

Subject(s) - medicine , immunogenicity , pneumococcal conjugate vaccine , pneumonia , immunization , pneumococcal pneumonia , pediatrics , streptococcus pneumoniae , immunology , antibody , antibiotics , microbiology and biotechnology , biology

In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-acquired pneumonia in adults aged ≥65 years was 46%. The long-term immunogenicity of PCV13 in pneumococcal vaccine-naive older adults was investigated as part of CAPiTA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research